Nivolumab demonstrates encouraging activity in metastatic colorectal cancer - Healio

IANS

Nivolumab demonstrates encouraging activity in metastatic colorectal cancer Healio CHICAGO — Nivolumab, with or without ipilimumab, appeared tolerable and demonstrated clinical activity for patients with microsatellite instability-high metastatic colorectal cancer, according to early results from the CheckMate 142 phase 2 study ... Nivolumab immunotherapy helps patients with advanced bladder cancerMedical Xpress Nivolumab shows promise in first-ever trial for patients with refractory, metastatic anal cancerScience Codex Expensive new cancer drug helps prolong patient survivalIrish Independent Cancer Therapy Advisor -Business Standard -AJMC.com Managed Markets Network all 9 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNFPj644eBq0DQusl5_hWcN-3oITRg&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779127862456&ei=XntVV6iVOo3J3gG397e4AQ&url=http://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/online/%257B4c6d6535-c1f8-4344-b60d-185f7e96dc43%257D/nivolumab-demonstrates-encouraging-activity-in-metastatic-colorectal-cancer
via IFTTT